Study summary

The objective of this study is to evaluate the efficacy and safety of ASP1517 when converted from recombinant human erythropoietin (rHuEPO) or darbepoetin alfa (DA), compared to DA in the treatment of anemia in non-dialysis chronic kidney disease patients. Another uncontrolled cohort will be included to evaluate the efficacy and safety of ASP1517 in patients converted from epoetin beta pegol (CERA). This study will also assess the safety/efficacy of long term treatment of ASP1517 (52 weeks).

Additional Study Details

Phase
3
Product
roxadustat
Product
roxadustat
DA
Type
Interventional
Masking
None (Open Label)
Enrollment number
334
Show Additional Study Details

Study documents

Scientific Results Summary
Available Language(s): English
Plain Language Summary
Available Language(s): Japanese

Get more information

Would you like more information about clinical trial sites that are recruiting participants for A study of Intermittent Oral Dosing of ASP1517 in Non-Dialysis Chronic Kidney Disease Patients with Anemia? Contact us by filling out your information to the right and we’ll respond to you.

  • A caregiver
  • A healthcare provider
  • A parent
  • A patient
  • A patient advocate
  • Algeria
  • Argentina
  • Armenia
  • Australia
  • Austria
  • Belarus
  • Belgium
  • Bosnia And Herzegovina
  • Brazil
  • Bulgaria
  • Canada
  • Chile
  • China
  • Colombia
  • Croatia
  • Czech Republic
  • Denmark
  • Dominican Republic
  • Egypt
  • Estonia
  • Finland
  • Former Serbia and Montenegro
  • France
  • Georgia
  • Germany
  • Greece
  • Guatemala
  • Hong Kong
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Ireland
  • Israel
  • Italy
  • Japan
  • Jordan
  • Kazakhstan
  • Latvia
  • Lebanon
  • Lithuania
  • Macedonia
  • Malaysia
  • Mexico
  • Montenegro
  • Morocco
  • Netherlands
  • New Zealand
  • Norway
  • Panama
  • Peru
  • Philippines
  • Poland
  • Portugal
  • Puerto Rico
  • Republic of Korea
  • Republic of Moldova
  • Romania
  • Russian Federation
  • Saudi Arabia
  • Serbia
  • Singapore
  • Slovakia
  • Slovenia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Taiwan, Province of China
  • Thailand
  • Turkey
  • Ukraine
  • United Kingdom
  • United States
  • Vietnam

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

    Locations

    Contact Us
    Contact Us
    Completed
    Site JP00049
    Aasahikawa, Hokkaido, Japan
    Withdrawn
    Site JP00070
    Hachioji, Tokyo, Japan
    Completed
    Site JP00024
    Minato-ku, Tokyo, Japan
    Completed
    Site JP00010
    Toyama, Toyama, Japan
    Completed
    Site JP00038
    Matsuyama, Ehime, Japan
    Completed
    Site JP00026
    Niigata, Niigata, Japan
    Completed
    Site JP00068
    Nagano, Nagano, Japan
    Completed
    Site JP00001
    Kamakura, Kanagawa, Japan
    Completed
    Site JP00064
    Sapporo, Hokkaido, Japan
    Completed
    Site JP00022
    Amagasaki, Hyogo, Japan
    Completed
    Site JP00012
    Sendai, Miyagi, Japan
    Completed
    Site JP00014
    Fukui, Fukui, Japan
    Completed
    Site JP00030
    Nagoya, Aichi, Japan
    Completed
    Site JP00015
    Koto-ku, Tokyo, Japan
    Completed
    Site JP00011
    Sakai, Osaka, Japan
    Completed
    Site JP00047
    Fujisawa, Kanagawa, Japan
    Completed
    Site JP00056
    Osaka, Osaka, Japan
    Completed
    Site JP00060
    Ota-ku, Tokyo, Japan
    Completed
    Site JP00037
    Hatsukaichi, Hiroshima, Japan
    Completed
    Site JP00066
    Nishinomiya, Hyogo, Japan
    Completed
    Site JP00045
    Kyoto, Kyoto, Japan
    Completed
    Site JP00019
    Toride, Ibaraki, Japan
    Completed
    Site JP00069
    Yao, Osaka, Japan
    Completed
    Site JP00042
    Kurume, Fukuoka, Japan
    Withdrawn
    Site JP00054
    Tsukushino, Fukuoka, Japan
    Completed
    Site JP00008
    Kitakyusyu, Fukuoka, Japan
    Completed
    Site JP00023
    Sashima-gun, Ibaraki, Japan
    Completed
    Site JP00003
    Sakura, Chiba, Japan
    Completed
    Site JP00039
    Hiroshima, Hiroshima, Japan
    Withdrawn
    Site JP00058
    Fukuoka, Fukuoka, Japan
    Completed
    Site JP00063
    Chiyoda-ku, Tokyo, Japan
    Completed
    Site JP00028
    Koga, Ibaraki, Japan
    Completed
    Site JP00041
    Tajimi, Gifu, Japan
    Completed
    Site JP00067
    Hino, Tokyo, Japan
    Completed
    Site JP00009
    Kasugai, Aichi, Japan
    Completed
    Site JP00004
    Koshigaya, Saitama, Japan
    Completed
    Site JP00034
    Oita, Oita, Japan
    Completed
    Site JP00062
    Tachikawa, Tokyo, Japan
    Completed
    Site JP00033
    Fukuoka, Fukuoka, Japan
    Completed
    Site JP00002
    Maebashi, Gunma, Japan
    Completed
    Site JP00044
    Matsuyama, Ehime, Japan
    Completed
    Site JP00025
    Adachi-ku, Tokyo, Japan
    Completed
    Site JP00061
    Osaka, Osaka, Japan
    Completed
    Site JP00021
    Toyohashi, Aichi, Japan
    Completed
    Site JP00032
    Hiroshima, Hiroshima, Japan
    Completed
    Site JP00005
    Izumisano, Osaka, Japan
    Completed
    Site JP00046
    Tsuchiura, Ibaraki, Japan
    Completed
    Site JP00055
    Okayama, Okayama, Japan
    Completed
    Site JP00050
    Kure, Hiroshima, Japan
    Completed
    Site JP00006
    Musashino, Tokyo, Japan
    Completed
    Site JP00013
    Kitakyusyu, Fukuoka, Japan
    Completed
    Site JP00053
    Naka, Ibaraki, Japan
    Completed
    Site JP00035
    Kanazawa, Ishikawa, Japan
    Completed
    Site JP00016
    Yokohama, Kanagawa, Japan
    Completed
    Site JP00057
    Kitakyusyu, Fukuoka, Japan
    Completed
    Site JP00031
    Morioka, Iwate, Japan
    Completed
    Site JP00065
    Fukuoka, Fukuoka, Japan
    Completed
    Site JP00051
    Nagoya, Aichi, Japan
    Completed
    Site JP00052
    Hitachi, Ibaraki, Japan
    Withdrawn
    Site JP00027
    Suita, Osaka, Japan
    Completed
    Site JP00040
    Kitakyusyu, Fukuoka, Japan
    Completed
    Site JP00059
    Higashiosaka, Osaka, Japan
    Completed
    Site JP00018
    Nagano, Nagano, Japan
    Completed
    Site JP00017
    Kasama, Ibaraki, Japan
    Completed
    Site JP00007
    Sapporo, Hokkaido, Japan
    Completed
    Site JP00020
    Koshigaya, Saitama, Japan
    Withdrawn
    Site JP00071
    Kagoshima, Kagoshima, Japan
    Completed
    Site JP00029
    Ageo, Saitama, Japan
    Completed
    Site JP00043
    Bunkyo-ku, Tokyo, Japan
    Completed
    Site JP00036
    Ueda, Nagano, Japan
    Completed
    Site JP00048
    Yokohama, Kanagawa, Japan

    Frequently Asked Questions

    Are clinical trials only for people with advanced cancer?

    While some clinical trials may focus on more advanced cancers, many trials are open to patients at various stages of their cancer. Each study has rules about who can take part. For example, only patients in a certain age group or those who have a certain type of tumor may be able to join.

    Will I have to stop my current treatment to participate in a clinical trial?

    Sometimes researchers want participants to keep taking their current treatments during a clinical trial. Other times, you may need to stop your current treatments for a while. If the investigational treatment doesn't work, you can usually go back to your original treatment plan.

    Should I be worried about getting a placebo?

    In cancer clinical trials, a placebo is only used if there is no other treatment for that type of cancer. This helps compare an investigational treatment to the placebo. Placebos are rarely used in cancer trials because the best available treatment, called the “standard of care”, is usually given instead.

    Do I need a referral from my doctor to take part in a study?

    Your doctor may not know about all the opportunities for clinical trials that are available to you. Talk to your doctor or other medical provider about clinical trial information that you find. They can help you decide if a clinical trial is right for you. If you do not find any options on this website, we recommend you visit an online public registry website like clinicaltrials.gov to see a wide variety of available clinical trials.

    Explore More

    1

    What are clinical trials?

    2

    Why are Clinical Trials Important?

    3

    Why Participate in a Clinical Trial?